Akebia Therapeutics Inc.

+0.10 (+3.12%)
Debt Financing / Related

Akebia Therapeutics Says Biovectra, Keryx Entered Into Amended, Restated Product Manufacture Agreement

Published: 09/11/2020 22:07 GMT
Akebia Therapeutics Inc. (AKBA) - Akebia Therapeutics Inc- Biovectra and Keryx Entered Into an Amended and Restated Product Manufacture and Supply and Facility Construction Agreement.
Akebia Therapeutics Inc- Keryx is Obligated to Reimburse Biovectra for Certain New Facility Construction Costs.
Akebia Therapeutics- Keryx to Buy Minimum Quantities of Auryxia Drug Substance That Are Lower Than Minimum Quantities Under Original Agreement.
Akebia Therapeutics Inc- Term of Amended and Restated Agreement Began September 4, 2020 and Ends December 31, 2026.